Core Insights - Henry Schein, Inc. (HSIC) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.34, reflecting a 12.6% increase year-over-year and surpassing the Zacks Consensus Estimate by 3.1% [1] - The full-year 2025 adjusted EPS was $4.97, up 4.8% from the previous year, also exceeding the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Fourth-quarter net sales reached $3.44 billion, a 7.8% increase year-over-year, beating the Zacks Consensus Estimate by 3.1% [3] - Full-year 2025 net sales totaled $13.18 billion, up 4% year-over-year, also surpassing the Zacks Consensus Estimate by 0.8% [3] Segment Analysis - Global Distribution and Value-Added Services segment sales rose 7% year-over-year to $2.89 billion, exceeding the forecast of $2.81 billion [4] - Global Dental Distribution merchandise sales increased 3.7% in constant currencies, while equipment sales grew by 9.1% at constant currencies, driven by strong growth in key markets [5] - Global Medical Distribution sales jumped 4.8% at constant currencies, despite a decline in the respiratory product category [5] - Global Specialty Products sales totaled $422 million, up 14.6% on a reported basis, reflecting strong growth in dental implants and endodontics [6] - Global Technology segment sales reached $173 million, an 8.4% increase on a reported basis, driven by cloud-based software adoption [7] Margin Performance - Gross profit for the quarter was $1.06 billion, a 7% increase year-over-year, but gross margin contracted by 19 basis points to 30.9% due to an 8% rise in the cost of sales [9] - SG&A expenses increased by 9.5% to $808 million, with adjusted operating profit remaining flat year-over-year at $255 million, leading to a contraction of the adjusted operating margin by 57 basis points to 7.4% [9] Liquidity and Share Repurchase - At the end of Q4 2025, the company had cash and cash equivalents of $156 million, up from $122 million a year earlier [10] - The cumulative net cash provided by operating activities was $712 million, down from $848 million in the previous year [10] - The company repurchased nearly 2.8 million shares at an average price of $71.10 per share, totaling approximately $200 million, with $780 million authorized for future repurchases [11] Future Guidance - For 2026, the company expects total sales growth between 3% and 5%, with the Zacks Consensus Estimate for sales at $13.53 billion, indicating a 3.5% year-over-year growth [12] - Non-GAAP diluted EPS for 2026 is projected to be in the range of $5.23 to $5.37, with the Zacks Consensus Estimate at $5.27 [12] Overall Assessment - The company demonstrated strong earnings and revenue growth, exceeding estimates, although margin contraction is a concern [13] - Solid sales growth was observed across all business segments, particularly in global equipment, specialty products, and technology [13]

Core Insights - Envista Holdings Corporation will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, with a fireside chat scheduled from 12:30 to 1:15 pm ET [1] Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [2] - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing various clinical needs for dental professionals [2] - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [2]

Core Insights - Envista Holdings Corporation released its 2024 Sustainability Report, emphasizing its commitment to sustainable and responsible business practices aimed at improving lives through partnerships with dental professionals [1][2]. Sustainability Initiatives - The report highlights key focus areas including expanding access to high-quality dental care, supporting colleagues and communities, environmental stewardship, and maintaining a strong ethical foundation [2][4]. - Envista donated $1.9 million in goods and services to enhance access to oral care health and education for underserved communities through the Envista Smile Project [7]. - The company completed its inaugural Scope 3 GHG emissions inventory to better manage its environmental footprint [7]. Performance Metrics - Envista achieved a 13% reduction in its safety incident rate, indicating improved workplace safety [7]. - The report reflects the collective efforts of teams across the organization, showcasing the company's dedication to creating lasting value for stakeholders [4]. Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on delivering innovative dental products and solutions [5]. - The company is positioned as one of the largest global dental products companies, with significant market presence in attractive segments of the dental industry [5].

Core Insights - Envista Holdings Corporation will report its financial results for the third quarter of 2025 on October 30, 2025, with a conference call scheduled for 2:00 PM PT [1] - The earnings press release and related materials will be available on the "Investors" section of Envista's website prior to the conference call [2] Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [3] - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [3] - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [3]

Core Insights - Envista Holdings Corporation will participate in the Stifel 2025 Jaws & Paws Conference on May 28, 2025, from 1:50 – 2:20 pm ET, with a live audio webcast available on its website [1] Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [2] - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [2] - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [2]